The transaction will enhance GSK's vaccines portfolio
GlaxoSmithKline Pharmaceuticals (‘GSK India') announces completion of its transaction with Novartis Healthcare (‘Novartis India'), where GSK India acquires Novartis' vaccines business and divests its marketed oncology portfolio to Novartis India.
This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis.
The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK's vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.